A daunting challenge.

Yet, discovering truly novel medicines that bring a genuine therapeutic benefit to patients and provide a position of leader to their developer seems to have become increasingly challenging.

Whereas industry-wide R&D expenses are skyrocketing, the pipeline of new molecular entities approved as drugs by regulatory agencies worldwide has been drying up, reaching all-time lows in the last few years.

The global R&D productivity of the pharmaceutical industry has been experiencing a steady decline for the last decade: why?

«	page 2/3	»
	1